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A methylome-wide mQTL analysis reveals associations
of methylation sites with GAD1 and HDAC3 SNPs
and a general psychiatric risk score
DM Ciuculete, AE Boström, S Voisin, H Philipps, OE Titova, M Bandstein, L Nikontovic, MJ Williams, J Mwinyi and HB Schiöth
Genome-wide association studies have identiﬁed a number of single-nucleotide polymorphisms (SNPs) that are associated with
psychiatric diseases. Increasing body of evidence suggests a complex connection of SNPs and the transcriptional and epigenetic
regulation of gene expression, which is poorly understood. In the current study, we investigated the interplay between genetic risk
variants, shifts in methylation and mRNA levels in whole blood from 223 adolescents distinguished by a risk for developing
psychiatric disorders. We analyzed 37 SNPs previously associated with psychiatric diseases in relation to genome-wide DNA
methylation levels using linear models, with Bonferroni correction and adjusting for cell-type composition. Associations between
DNA methylation, mRNA levels and psychiatric disease risk evaluated by the Development and Well-Being Assessment (DAWBA)
score were identiﬁed by robust linear models, Pearson’s correlations and binary regression models. We detected ﬁve SNPs (in
HCRTR1, GAD1, HADC3 and FKBP5) that were associated with eight CpG sites, validating ﬁve of these SNP–CpG pairs. Three of these
CpG sites, that is, cg01089319 (GAD1), cg01089249 (GAD1) and cg24137543 (DIAPH1), manifest in signiﬁcant gene expression
changes and overlap with active regulatory regions in chromatin states of brain tissues. Importantly, methylation levels at
cg01089319 were associated with the DAWBA score in the discovery group. These results show how distinct SNPs linked with
psychiatric diseases are associated with epigenetic shifts with relevance for gene expression. Our ﬁndings give a novel insight on
how genetic variants may modulate risks for the development of psychiatric diseases.
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INTRODUCTION
Genome-wide association studies have shown that the level of
DNA methylation, probably the best-studied epigenetic mark, is
partly associated with nearby single-nucleotide polymorphisms
(SNPs).1–3 An increasing number of SNPs have been associated
with the pathogenesis of psychiatric disorders.4 In this context,
genetic variants in various genes, such as COMT, BDNF, GAD1 or
APOE,5–8 are repeatedly highlighted. However, the exact mechan-
isms behind the interplay between methylation levels and
polymorphisms are poorly understood. A further elucidation of
the interaction between genetic and epigenetic mechanisms may
allow a better understanding of the mechanistic role of genetic
polymorphisms in development of complex psychiatric diseases.
Brain maturation occurs during adolescence through processes
such as synaptic pruning.9 Normal brain development and
function are highly dependent on DNA methylation as stable
chemical modiﬁcation of cytosines in CpG dinucleotides. The
importance of these reactions was demonstrated for several
cognitive processes, such as learning and memory10 and neuronal
activity.11 This includes a previous study that showed a relation-
ship between differential DNA methylation and genes involved in
γ-aminobutyric acid (GABA)-ergic pathways.11 In 2013, Domschke
et al.12 revealed that, compared with healthy controls, GAD1
methylation levels were lower in adults with panic disorder.
Interestingly, a previous study showed that individuals homo-
zygous for the major allele of rs4680 (within COMT) showed stress-
related methylation changes, which was not observed in
heterozygotes.13 Higher levels of DNA methylation repress
transcription by inhibiting the binding of transcription factors or
by changing microRNA expression.14 These ﬁndings indicate that
changes in DNA methylation may contribute to the compensation
and/or modulation of interindividual genetic variation15 and may
be able to induce alterations in the complex regulatory landscape
of gene expression levels in psychiatric disorders.
For we believe the ﬁrst time, our study speciﬁcally investigates
to what extent 37 psychiatric disease-related SNPs are connected
to methylation changes (methylation quantitative trait loci (mQTL)
analyses) in 223 adolescent individuals showing a differently
strong risk for the development of psychiatric illnesses, as
evaluated by the Development and Well-Being Assessment
(DAWBA) band score. In this context, we further scrutinize
whether differentially methylated regions associated with genetic
variations inﬂuence gene expression, as well as to what extent
they modulate the risk for disease development.
MATERIALS AND METHODS
Subjects
Discovery data set. The present study included a total of 130 adolescent
volunteers aged between 14 and 16, recruited between November 2012
and January 2013. The included subjects were randomly selected from
public school in Uppsala County, with the aim to investigate potential
psychiatric risk factors in youth. Self-reported information regarding basic
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physiological parameters, for example, height, age and medication, was
provided by the participants. In addition, body weight was measured for
body mass index calculation. This data set served as discovery data set in
our study.
Replication data set. In the replication stage, 93 samples from the same
study, but characterized later in the time frame 2013–2014, were
evaluated. The selection criteria included individuals with a risk for
psychiatric diagnoses higher than 15%, aged between 14 and 16 years. The
same parameters as in the discovery group were recorded for these
individuals. Both studies were approved by the Regional Ethics Committee
in Uppsala, and all participants gave their written informed consent.
Expression data set. Eleven healthy male volunteers aged between 18 and
40 years were recruited from the region of Uppsala, Sweden, between
2013 and 2014. Blood analyses were performed before and after a meal
intake. The analyses regarding methylation and expression proﬁles were
corrected for proportions of different cell types. More details about this
healthy group as well as about preprocessing of the methylation
specimens and expression patterns in this cohort can be found
elsewhere.16
Phenotype assessment
The risk for psychiatric diseases was assessed by performing a DAWBA
web-based interview designed for individuals in the age range 5–17 years
to generate Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
and International Classiﬁcation of Diseases (ICD)-10-based psychiatric
diagnoses. DAWBA consists of two versions of individual standardized
questionnaires, administrated to adolescents and their parents. Computer-
generated diagnostic predictions were only used in the present study. The
average of the ‘probability bands’ was computer-assisted generated
referring to several diagnoses such as anxiety disorders, depression,
post-traumatic stress disorder, autism, separation anxiety disorder and
obsessive compulsive disorder. DAWBA diagnoses are given in the range of
less than 0.1% to over 70% probability that the individual could experience
one of the mentioned DSM-IV or ICD-10-based diagnosis. A more detailed
description of DAWBA-level bands and details about validation steps are
given in Goodman et al.17
Genotyping and DNA methylation
All study participants were genotyped using the Illumina Golden Gate
array at the SNP&SEQ SciLife Platform at Uppsala University. On the basis
of the literature search regarding associations of risk variants with
psychiatric disorders, that is, eating disorders, panic disorder, obsessive-
compulsive disorder, major depression and bipolar disorder,18 and on their
inclusion in the microarray-assisted genotyping approach, we investigated
a set of 37 SNPs with minor allele frequency higher than 5%. All SNPs
were checked for Hardy–Weinberg equilibrium using χ2-test. SNPs
were considered in disequilibrium if Po0.01. Each SNP was coded
as 0 (homozygous major allele), 1 (heterozygous genotype) or 2
(homozygous minor allele). A dominant model was assumed for the SNPs.
Genome-wide DNA methylation analysis was carried out using the Illumina
Inﬁnium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA,
450k). Description of experimental procedures can be found in
Supplementary File 1.
DNA methylation preprocessing
Preprocessing of methylation data included background correction, probe
exclusion, adjustment of type I and type II probes and removal of batch
effects. The robust pipeline also included outlier detection by principal
component analyses and white blood cell correction (Supplementary File
2). These analysis steps were performed using the lumi, sva, limma,
wateRmelon and FactoMineR packages available in Bioconductor and
operable in the R version 3.1.3 software (R is freely available under the GNU
General Public License). The experimental ﬂow of the discovery set is
presented in Figure 1.
Criteria of sample exclusion
Samples were excluded based on the following criteria: samples that were
shown to be outliers in any of the ﬁve quality-control plots generated by
MethylAid19 (rotated M versus U plot, overall sample-dependent control
plot, bisulﬁte conversion control plot, overall sample-independent control
plot and detection P-value plot) without changing the default thresholds (0
sample) and samples that were outliers for the ﬁrst two principal
components (1 sample). The procedure was repeated in the same manner
for the validation cohort where none of the samples were excluded.
Evaluation of DNA methylation sites and mQTLs in brain and
blood
To investigate to what extent epigenetic shifts in whole blood are of
functional relevance in the brain, we correlated chromatin marks in brain
and blood. On the basis of the availability of chromatin state data derived
using Hidden Markov Models (HMMs), the following eight brain tissues
were analyzed: brain angular gyrus, brain anterior caudate, brain cingulate
gyrus, brain hippocampus, brain inferior temporal lobe, brain substantia
nigra and peripheral blood mononuclear primary cells. Data were loaded
from Roadmap Epigenomics Project of 37/hg19 version of human genome
in the WashU Epigenome Browser. For easier visualization, the 18-state
model for the production of the segmentations according to gene-
regulatory role was reduced to ﬁve regions, indicating the functionality by
different colors: red, for active/ﬂanking active/bivalent/poised transcription
start site (TSS); yellow, for active/bivalent/genic enhancer; orange, for
ﬂanking bivalent TSS/enhancer; green, for active transcription; and grey,
for repressed polyComb state. Using this reliable tool, information about
regions representing chromatin states overlapping signiﬁcant CpG sites
and mQTL was obtained. In addition, potential regulatory effects of the
CpG sites on multiple genes and the speciﬁcity of the association with
mQTLs were considered by examining long-range interactions. The long-
range interaction mapping was derived using chromatin analysis by
paired-end tag sequencing libraries from the ENCODE consortium. Four
different cell lines, that is, erythrocytic leukaemia cells (K562), breast cancer
(MCF-7), cervical cancer (HelaS3) and human colon carcinoma (HCT-116),
targeting the transcription factors RNA polymerase II and CCCTC-binding
factor (CTCF), an insulator protein with diverse functions,20 were used. Data
were downloaded from the WashU Epigenome Browser, 37/hg19 version.
Ubiquitous, tissue-speciﬁc and cell type-speciﬁc in vivo transcribed
enhancers
In order to get information about the in vivo relevance of the CpG sites for
expression, we used data produced by the FANTOM5 project. Ubiquitous,
tissue-speciﬁc (brain, blood) and cell type-speciﬁc (T cells, neurons) in vivo
enhancers as deﬁned by CAGE tags were downloaded from the
Transcribed Enhancer Atlas website.21
Linkage disequilibrium of mQTLs
Linkage disequilibrium (LD) data were obtained using SNAP Proxy web
tool,22 with Northern Europeans from Utah (CEU) as the population
selection. Two SNPs having r2 = 1 and D′= 1 were considered in perfect LD.
Statistical analysis
Beta values of methylation were used for graphical illustration. For
statistical analysis, we transformed the beta values to M-values, which have
been shown to be statistically more robust.23 Statistical analyses were
performed using Bioconductor, R (version 3.1.3) and SPSS software (version
22; SPSS, Armonk, NY, USA). To guarantee the reliability and power of data
analyses, a conﬁrmatory approach was chosen, investigating two
independent cohorts with regard to SNP–methylation interaction.
Linear models. The association between SNPs and DNA methylation was
tested through linear models using the limma R package, suitable for large-
scale methylation studies,16,24 applying an empirical Bayes method based
on a moderated t-statistic. We assumed a linear model where the M-values
of each individual CpG site i were used as the quantitative dependent trait
and categorical variables, for example, genotype (G) and sex (S), together
with continuous variables, for example, age (A), body mass index, PC1 and
PC2, were included as covariates. The coefﬁcient bi represents the strength
of association between methylation levels and variable of interest and εi
refers to the unexplained variability.
Mi ¼ ai þ biGþ biSþ biAþ bi BMI þ bi PC1 þ bi PC2 þ εi
All analyses were adjusted for multiple testing using the Bonferroni
correction. Adjusted two-sided P-valueo0.05 was considered signiﬁcant. A
known limitation of the epigenome-wide association analyses is an inﬂated
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number of false positives.25,26 Therefore, the genomic inﬂation factor (λ) for
all SNP–CpG analyses was calculated using the estlambda function of
GenABEL R package.27 The analyses were restricted to 500 kb up- and
downstream of each SNP. The targeted analyses were performed applying
a likelihood ratio test, with lrtest function of the lmtest package.28 Here, to
correct for false positives, two-sided q-values were calculated using the
qvalue package29 and values o0.05 were considered signiﬁcant.
Binary regression models. Signiﬁcant CpG sites were tested in relationship
with the general DAWBA band. Binominal tests were applied between
DAWBA score outcome and continuous M-values of the individual CpG site
and adjusting for body mass index, age, sex and DAWBA version, that is,
score generated based on adolescent questionnaire or both adolescent
and parent questionnaires. For these analyses, DAWBA scores were ranked
into two categories (0 and 1). Individuals from the discovery data set with a
DAWBA risk score below 50% were deﬁned as ‘Low risk’ (category 0; 87.4%)
and included the levels 0 (o0.1%), 1 (≈0.5%), 2 (≈3%) and 3 (≈15%) of
DAWBA. The individuals with levels 4 (≈50%) and 5 (470%), having a risk
higher than 50%, were assigned to the ‘High risk’ category (12.6%). The
same subgroups were built in the replication set. According to the DAWBA
version, 37.2% of individuals from the discovery set and 60.2% from the
replication set had the DAWBA-level band generated based only on
adolescent questionnaire. Separate analyses including only the complete
DAWBA general band score, based on both adolescent and parent
questionnaires, were performed for the discovery and replication data sets,
adjusting for body mass index, sex and age. Two-tailed P-valueso0.05
were considered signiﬁcant.
Robust linear regression models and Pearson’s correlations. Validated DNA
methylation changes were tested in association with the gene expression
levels, computing robust linear regression models and Pearson’s correlations
in R environment. Robust linear models are recommended to be used in
case of a small sample size, to account for any outliers or heteroscedasticity
in the data.30 The robust package was used for these computations. The
sated state of the 11 individuals was chosen to perform these analyses
because of the similarity with the discovery and replication data sets. The
transcripts corresponding to signiﬁcant CpG loci were determined from the
original Illumina annotation referring to the nearest gene to each probe or
by a potential regulatory effect on other genes as described in the literature.
Two-sided P-values o0.05 were considered signiﬁcant.
RESULTS
Study data sets
The outcome of demographic and clinical variables of the discovery
and replication set is illustrated in Table 1. The discovery data set
was retrieved from 129 adolescents, who were in the majority
female subjects. The mean age was 15.33± 0.60 years. There were
no substantial demographic differences between the discovery and
replication groups. The subjects from both cohorts were categor-
ized into two categories according to the level band score of
DAWBA, that is, in the ‘Low risk’ (n=113, respectively, n=44) and
‘High risk’ group (n=16, respectively, n=49). The DAWBA general
band was used as the outcome variable in the analyses, whereas
separate symptoms were not analyzed, given the small number of
cases in the discovery cohort (Supplementary Table 1A).
Effect of cell heterogeneity across samples
Our mQTL analyses were adjusted for cell-type proportions
detected in whole blood. To test the reliability of the correction
for blood cell proportions, we calculated the ﬁrst two principal
Figure 1. Workﬂow of the study. DAWBA, Development and Well-Being Assessment; mQTL, methylation quantitative trait loci; SNP, single-
nucleotide polymorphism.
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components for unadjusted beta values. Subsequently, we
performed Pearson’s correlation analyses between the ﬁrst two
principal components and cell-type estimations, that is, CD4
+T cells, CD8+T cells, B cells, NK, Mono and Gran, before and after
adjustment (Figure 2). The importance of cell-type correction is
proven by evaluating the percentage of explained variance. The
heatmap shown in Figure 2 illustrates that the cell-type correction
accounted for cell heterogeneity. The ﬁrst and second principal
components (PC1 and PC2), calculated based on the unadjusted
beta values, explained 29% variance, whereas the same ﬁrst two
principal components applied to beta values after blood cell
estimation accounted for 8%.
Relationship between genotype and methylation proﬁles
The study workﬂow is illustrated in Figure 1. After having
performed the necessary preprocessing steps for the Illumina
450k array data, 305 147 CpG loci were investigated for their
association with 37 SNPs, which were earlier associated with
psychiatric diseases. Analyses were performed based on the data
of 129 individuals from the discovery group after one outlier was
excluded. Top hit associations and related unadjusted P-values of
all mQTL are shown in Supplementary Table 2. We detected a
signiﬁcant association for eight SNP–CpG pairs (Pbonfo0.05,
corresponding to Po1.6 × 10− 7), that is, a signiﬁcant relationship
between the level of DNA methylation at a distinct CpG site and a
polymorphism (Table 2). These eight pairs consisted of ﬁve SNPs
(13.5% of tested SNPs) and seven CpG sites (0.002% of tested CpG
sites). The SNPs included rs10914453, rs2058725, rs2241165,
rs2530223 and rs9296158 and are located in or nearby genes
previously related to psychiatric disorders, that is, HCRTR1, GAD1,
HDAC3 and FKBP5. The SNP rs2241165 is in perfect LD with the
GAD1 variant rs2270335. The closest genes to the detected
signiﬁcant CpG sites included PEF1, GAD1, C11orf9, DIAPH1 and
PCDHGC3.
A highly signiﬁcant positive association was found for the
methylation site cg01089319 (GAD1 gene) with two genetic
variants of the gene GAD1 (rs2058725 (P= 0.0003) and rs2241165
(P= 2.61e− 06)). In addition, cg01089249 showed a strong
relationship to the variant rs2241165 (GAD1, P= 1.44e− 02). The
CpG site represented by cg24137543 was signiﬁcantly associated
with rs2530223 within HDAC3 (P= 0.009). All signiﬁcant identiﬁed
methylation sites on the genome-wide scale were validated using
targeted analyses, except in case of cg18766608, which was not
located in the range of 500 kb up- or downstream of rs2058725
(data not shown).
We sought to increase the power of our analyses by conﬁrming
our ﬁndings in a replication set comprising of 93 individuals.
During this step the limma models were restricted to ﬁve genetic
variants signiﬁcantly associated with DNA methylation levels in
the discovery set. After correction for multiple testing, ﬁve SNP–
CpG pairs were validated, including the SNPs rs10914453
(HCRTR1), rs2058725 (GAD1), rs2241165 (GAD1) and rs2530223
(HDAC3). Four of seven CpG loci were conﬁrmed to have
associations with the genetic variants in the same direction as in
the discovery data set. All associations with a Pbonfo0.05,
corresponding to Po1.58 × 10− 7, were considered signiﬁcant. In
line with the results obtained in the discovery data set, the CpG
site cg01089319 was signiﬁcantly associated with the GAD1 SNPs
rs2058725 (P= 5.89e− 07) and rs2241165 (P= 5.98e− 06). The
other top two associations detected in the discovery group were
also conﬁrmed in the replication group (cg24137543 and
rs2530223 (P= 7.59e− 06); cg01089249 and rs2241165
(P= 1.33e− 06; Table 2).
Given our hypothesis that a subset of SNPs are associated with
methylation levels, DNA methylation levels were stratiﬁed
according to the number of minor alleles in the discovery data
set (Figure 3). Carriers of the minor allele (G allele) of GAD1 SNPs
rs2058725 and rs2241165 showed higher methylation levels at
cg01089319 and cg01089249. Conversely, carriers of the ancestral
allele at rs2530223 showed higher methylation levels. In the
discovery cohort, the inﬂation factor was below 1, except for one
variant at rs2530223 (λ= 1.09). For the replication set all λ values
were below 1.
Genomic context of the CpG sites signiﬁcantly associated with
GAD1 and HDAC3 mQTLs
The four CpG sites signiﬁcantly associated with GAD1 and HDAC3
SNPs were further investigated with regard to the tissue speciﬁcity
of the association and their potential functional implication in
gene regulation. Therefore, we compared the functional role of
these CpG sites in different brain tissues and blood cells with
regard to gene regulatory relevance and/or in interaction with
nearby genes, offering a broad landscape between chromatin
states and potential regulatory activity. All four CpG sites show
Figure 2. Illustration of cell-type composition effect using principal
component analysis (PCA). The heatmap indicates signiﬁcant
correlations between the ﬁrst two principal components and the
estimations of blood cell types. After cell-type correction, no
association between the ﬁrst two principal components and cell
type are longer observed. Bcell, B cell; Gran, granulocyte; Mono,
monocytes; NK, natural killer; PC, principal component.
Table 1. Discovery and replication data sets’ description
Discovery set (n= 129) Replication set (n= 93)
Low risk High risk P-valuea Low risk High risk P-valuea
Sex (male) n (%) 33 (25.6) 4 (3.1) NS 14 (15.0) 5 (5.3) 0.019
Age (years)± s.d. 15.34± 0.59 15.25± 0.68 NS 15.77± 0.61 15.70± 0.64 NS
BMI (kg/m2)± s.d. 21.37± 2.89 24.68± 6.3 NS 22.23± 3.16 22.06± 3.32 NS
Abbreviations: BMI, body mass index; DAWBA, Development and Well-Being Assessment. Continuous variables are shown as mean± s.d. Individuals with a
general DAWBA psychiatric risk score below 50% were deﬁned as ‘Low risk’ and included 0 (o0.1%), 1 (≈0.5%), 2 (≈3%) and 3 (≈15%) level bands of the
DAWBA score. Individuals with level bands 4 (≈50%) and 5 (470%), having a risk higher than 50%, were assigned to the ‘High risk’ category. aTwo-tailed
analysis tests the difference between the ‘Low risk’ and ‘High risk’ group using the Student’s t-test for continuous variables and the χ2-test for categorical
variables. Bold value signiﬁes P-valueso0.05.
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interaction arcs, with mQTLs indicating that the associations may
not be tissue-speciﬁc. The cg01089319 site (GAD1) did not show
relevant long-range interactions with other genes (data not
shown). Instead, it is located within an enhancer region of
functional relevance in the hippocampus and peripheral blood
mononuclear primary cell, according to the results obtained with
the tool chromHMM (Figure 4). The second CpG site in GAD1
(cg01089249) is also located in an enhancer region, but is only
detectable in the hippocampus. The CpG site cg24137543
associated with rs2530223 (HDAC3) is located within important
gene regulatory regions, that is a TSS, an enhancer or ﬂanking
active TSS/enhancer throughout all investigated brain tissues and
peripheral blood mononuclear primary cell. Interestingly, this CpG
site is located in or show long interactions with the TSS or
enhancer regions of γ-protocadherins (γ-Pcdh) subfamily genes
(Figure 5).
Relationship between methylation changes at signiﬁcant and
validated CpG sites and gene expression
The genomic context of validated CpG sites (cg00112260,
cg01089319, cg01089249 and cg24137543) led to a more detailed
analysis regarding their role in gene transcription (Table 3). We
tested associations between CpG loci from GAD1 (cg01089319 and
cg01089249) and expression levels of GAD1, DNMT1, DNMT3a (ref.
31) and COMT (ref. 5). We also evaluated the relationship between
methylation changes at cg24137543 and the expression of HDAC3
and γ-Pcdh subfamily. After computing robust linear regression
models, three signiﬁcant associations between the methylation
level at cg01089319 and GAD1 expression (P= 0.03, coefﬁcient =
− 1.14), as well as the methylation level at cg24137543 and both
HDAC3 and PCDHGA6 expression levels (P= 1.25e− 06, coefﬁ-
cient = 1.49 and respectively, P= 0.014, coefﬁcient =− 1.44) were
identiﬁed. Using Pearson’s correlation analysis, the latter associa-
tion between methylation levels at cg24137543 and PCDHGA6
expression was validated (P= 0.04, correlation coefﬁcient (cor) =
− 0.60). Furthermore, an additional negative correlation between
cg01089249 (GAD1) and COMT expression (P= 0.04, cor =− 0.61)
was detected. No correlations were identiﬁed between methyla-
tion levels at cg00112260 and the expression of the HCRTR1
associated mQTL (Table 3).
Relationship between methylation levels at validated CpGs and
DAWBA risk scores
We tested the association between methylation changes of
signiﬁcant CpG loci and DAWBA score in subsequent binary
regression analyses initially in the discovery cohort. The methyla-
tion of CpG site cg01089319 was found to be strongly and
signiﬁcantly associated with two categories of the DAWBA general
score, that is, ‘Low risk’ and ‘High risk’ score (P= 0.031, odds
ratio = 3.03, 95% conﬁdence interval 1.10–8.32). The separate
analysis supported the association between methylation levels at
cg01089319 and the complete DAWBA general bands (P= 0.033).
The differences in methylation levels at cg01089319 are 3%
between carriers and non-carriers of rs2058725 and rs2241165,
respectively. These ﬁndings were not conﬁrmed in the validation
set, which has a more homogeneous composition (Supplementary
Table 1B).
DISCUSSION
To our knowledge, this is the ﬁrst study that investigates the
association between SNPs known to be related to different
psychiatric diseases and the genome-wide methylation pattern. By
further investigating the association of SNP-related CpG sites with
gene expression and phenotypic psychiatric disease measures,
this paper elucidates novel mechanistic insights on how the
detected CpG sites in focus may inﬂuence the expression of genesT
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hypothesized to have a pathogenetic role in psychiatric diseases
in adolescents.
We detected that the methylation state of eight CpG sites was
associated with SNPs and replicated ﬁve of these pairs in whole
blood, after cell-type confounding and strict Bonferroni correction.
These signiﬁcant variants include the following genes HCRTR1,
GAD1, HDAC3 and FKBP5, earlier associated with neuropsychiatric
diseases.32 Interestingly, the GAD1 SNP rs2241165 is in perfect LD
with rs2270335, which has been previously linked with grey
matter loss in childhood-onset schizophrenia.33 Moreover, we
extended our analyses on the relationship of the methylation
levels with gene expression, identifying associations with GAD1
and COMT expression. Importantly, one of our identiﬁed CpG
site (cg01089319) within the GAD1 gene is signiﬁcantly hyper-
methylated in the individuals with higher general psychiatric risk
(DAWBA) score in discovery data set. These ﬁndings point
that these SNPs are partly reﬂecting epigenetic regulatory
loops, changing the expression of important psychiatric
susceptibility genes.
Previous studies revealed that epigenetic shifts appear to be
especially of importance for the regulation of pathways involved
in neuronal development.34–38 Indeed, in our study on adolescent
individuals, we found ﬁve psychiatric risk variants to be associated
with DNA methylation. One of the most striking ﬁnding is the role
of these methylation shifts in GAD1 gene expression. GAD1 is a
critical enzyme for the synthesis of GABA, the most important
inhibitory neurotransmitter in the brain. Here we show that the
two GAD1 variants are signiﬁcantly associated with DNA
methylation of the CpG sites cg01089319 and cg0108924,
detecting a difference of 3% between carriers and non-carriers
of the minor allele. Importantly, chromatin states map the CpG loci
in an enhancer region in the hippocampus (Figure 4), an
observation that is consistent with the role of GAD1 expression
in the hippocampus.39
Alterations in GABA activity have been shown to be a result of
lower GAD1 expression induced by epigenetic mechanisms.40,41
Lower GABA concentrations were found in patients with mood
disorder, bipolar disorder or depression compared with
controls.42–44 Another gene, which might regulate GABA neuronal
excitability, is COMT (ref. 45). This enzyme is involved in dopamine
inactivation. The exact mechanism of how this neurotransmitter
regulates GABAergic activity is, however, unclear. On the basis of
our results, we support the hypothesis of a potential functional
interaction of COMT and GAD1 in the GABA circuit.5,46 We
Figure 3. Associations between genotype data at the four validated SNPs and methylation levels at three unique CpG sites (cg01089319,
cg01089249 and cg24137543) in the discovery set. Distribution of the beta values at the methylation sites is illustrated for individuals carrying
zero, one and two minor alleles. *P-valueo0.05 (Student’s t-test); **P-valueo0.01 (Student’s t-test); ***P-valueo0.001 (Student’s t-test). SNP,
single-nucleotide polymorphism.
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identiﬁed a signiﬁcant inverse correlation between methylation
levels at cg01089249 (GAD1) and COMT expression. However, we
did not observe a change in GAD1 messenger RNA (mRNA)
expression. This could be because of the fact that GAD1
undergoes important post-transcriptional modiﬁcation.47 The lack
of correlations between methylation levels and mRNA proﬁles can
be attributed to the effect of methylation changes on alternative
splicing48 or to an unspeciﬁc signal as multiple transcripts are
recognized by one probe.49
The small difference in DNA methylation at cg01089319
observed is signiﬁcantly associated with the level of DAWBA
general band. Our regression model accounted for 20% of the
variation of the risk level measured by DAWBA in the discovery
set. The methylation levels at this CpG site are associated with two
variants within the GAD1 gene, suggesting an additional
mechanism of how these SNPs affect the risk for different
psychiatric disorders. This ﬁnding allows the hypothesis that
genetic variants and associated methylation changes are not
disorder-speciﬁc but associated to several psychiatric disorders.50
Importantly, the discovery cohort is a population-based cohort,
whereas the replication cohort has a more homogenous
composition with regard to DAWBA scores. This might be a
possible reason that this association was not validated.
Another variant that was associated with differences in DNA
methylation proﬁles was the exonic SNP rs2530223, within the
gene HDAC3. This gene is strongly expressed in the
hippocampus.51 The enzyme HDAC3 was shown to have a role
in normal brain development52 and speciﬁcally in long-term
memory.53 Moreover, this protein represses the transcription
factor GATA-2 (ref. 54), which modulates GABAergic neurons in
the midbrain.55 The associated CpG site cg24137543 is located in
sequence areas of regulatory importance throughout all brain
regions and blood cells according to chromatin states mapping
and shows interaction arcs with the mQTL (Figure 4). This
observation suggests that the detected association may not be
tissue-speciﬁc. Furthermore, methylation at cg24137543 was
inversely correlated with PCDHGA6 gene expression. This associa-
tion supports our previously identiﬁed interaction with
transcription factor sites in γ-Pcdh subfamily genes from
chromatin analysis by paired-end tag sequencing libraries. γ-
protocadherin genes were shown to be expressed in synapses56
and deﬁciency of γ-Pcdh transcripts differentially inﬂuences
GABAergic neurons in mice.57 The cg24137543 location within
an in vivo enhancer region of neurons strengthens the evidence
for a potential modulatory effect on γ-Pcdh transcripts in neurons.
The strength of our study is the genome-wide approach,
revealing the most relevant changes of the CpG sites. Consistently,
we could validate the associations of the identiﬁed CpG sites with
distinct SNPs by independent local analyses. We speciﬁcally
investigated 37 SNPs known to be strongly associated with
psychiatric diseases. It cannot be excluded that additional SNPs
may show similar association patterns with methylation. Although
we accounted for different cell-type proportions in blood, the
preferred tissue for biomarker analysis, additional studies in brain
tissue would provide valuable information about additional tissue-
speciﬁc SNP/CpG site associations and connected expression
changes, which are not reﬂected in blood. Furthermore, it will be
of value to validate the CpG/mQTL associations in larger cohorts,
taking changes of the transcriptional expression of associated
genes into account. Finally, to increase the power of the analysis
on the association between methylation levels and the DAWBA
general bands, we combined scores generated exclusively by
adolescent questionnaires with scores generated based on both
adolescent and parent questionnaires. As the adolescent ques-
tionnaire does not cover all behavioral and hyperactivity-type
disorders17 present in the parent questionnaire, this heterogeneity
in our primary outcome variable could bias downstream results.
However, we adjust for this potential bias by controlling for this
difference in our analysis. In addition, the separate analysis
including only the complete DAWBA general band score, based on
both adolescent and parent questionnaires, conﬁrmed the
positive association between level of methylation and DAWBA
score. We were speciﬁcally interested in analyzing SNP–methyla-
tion interactions in individuals at risk for psychiatric diseases in
adolescence, encompassing multiple psychiatric diseases and
neurobiological changes. Future studies of larger sample size are
Figure 4. Genomic context of the most signiﬁcant CpG sites associated with SNPs rs2241165 and rs2058725. Genomic positions of RefSeq
genes are displayed in the top part, indicated by blue arrows. The positions of the signiﬁcant CpG sites are highlighted by black lines. For the
investigation of speciﬁcity of the associations, long-range interactions were derived from four cell lines targeting two transcription factors.
Associations are represented by arcs. Only long-range interactions containing signiﬁcant CpGs were illustrated. The intensity of the arc is
proportional to the strength of the interaction between the two regions. As analyses were performed based on data obtained in blood,
chromatin marks overlapping in brain and blood cells were investigated. Chromatin states of eight tissues downloaded from the 37/hg19
WashU Epigenome Browser are illustrated. Each functional role of a segment is indicated by a particular color. BrainAC, brain anterior caudate;
BrainAG, brain angular gyrus; BrainCG, brain cingulate gyrus; BrainDPC, brain dorsolateral prefrontal cortex; BrainHIPPO, brain hippocampus;
BrainITL, brain inferior temporal lobe; BrainSN, brain substantia nigra; PBMC, peripheral blood mononuclear primary cells; SNP, single-
nucleotide polymorphism; TSS, transcription start site.
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Figure 5. Genomic context of the most signiﬁcant CpG sites (cg08155325 and cg24137543) associated with SNP rs2530223. Genomic positions
of RefSeq genes are displayed in the top part, indicated by blue arrows. The positions of the signiﬁcant CpG sites are highlighted by black lines.
For the investigation of the potential regulatory effect of the signiﬁcant CpG sites on other genes and of the speciﬁcity of the associations, long-
range interactions were derived from four cell lines targeting two transcription factors. Associations are represented by arcs. Only long-range
interactions containing signiﬁcant CpGs are illustrated. The intensity of the arc is proportional to the strength of the interaction between the
two regions. As analyses were performed based on data obtained in blood, chromatin marks overlapping in brain and blood cells were
investigated. Chromatin states of eight tissues downloaded from the 37/hg19 WashU Epigenome Browser are illustrated. Each functional role of
a segment is indicated by a particular color. BrainAC, brain anterior caudate; BrainAG, brain angular gyrus; BrainCG, brain cingulate gyrus;
BrainDPC, brain dorsolateral prefrontal cortex; BrainHIPPO, brain hippocampus; BrainITL, brain inferior temporal lobe; BrainSN, brain substantia
nigra; PBMC, peripheral blood mononuclear primary cells; SNP, single-nucleotide polymorphism; TSS, transcription start site.
Table 3. Associations of the signiﬁcant and validated CpG sites and gene expressions in 11 adult healthy individuals
CpG site Affymetrix transcript IDa Gene expression Coef.b P-valueb Coef.c P-valuec
cg01089319 NM_000817 GAD1 − 1.14 0.03 — NS
NM_001130823, NM_001379 DNMT1 —- NS — NS
NM_022552, NM_153759 DNMT3A — NS — NS
NM_144589 COMT — NS — NS
cg01089249 NM_000817 GAD1 — NS — NS
NM_001130823, NM_001379 DNMT1 — NS — NS
NM_022552, NM_153759 DNMT3A — NS — NS
NM_144589 COMT — NS − 0.61 0.04
cg24137543 NM_003883 HDAC3 1.49 1.25e−06 — NS
NM_018919 PCDHGA6 − 1.44 0.01 − 0.60 0.04
cg00112260 NM_001525 HCRTR1 — NS — NS
Abbreviations: Coef, coefﬁcient; NS, nonsigniﬁcant. aAccording to GeneChip Human Gene 2.1 ST Array annotation ﬁle. bCorrelations between methylation
levels at CpG sites (M-values) and gene expression levels were performed using robust linear regression models. Shown are P-values and coefﬁcients.
cCorrelations between methylation levels at CpG sites (M-values) and gene expression levels are performed using Pearson’s correlation analyses. Shown are P-
values and coefﬁcients. Bold values signify P-valueso0.05.
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needed to further investigate the associations in speciﬁc diseases,
such as, for example, depression, general anxiety and obsessive-
compulsive disorder.
In conclusion, we succeeded to deﬁne an epigenetic landscape
that associates with genetic markers related to psychiatric
diseases and gene expression. Our ﬁndings show that the effect
of several important psychiatric disease-related SNPs appears at
least partly to be the result of associated epigenetic shifts that
lead to alterations in GABAergic signaling in the human brain.
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